Skip to content

A CHF 1 billion contract for Bachem Group

Share this article

The contract covers the delivery of a large volume of peptides over a five-year period from 2025-2029, and follows the conclusion of two large volume contracts announced in September 2022. The customer’s name is undisclosed.


Bachem is pursuing an investment program across all sites to expand capacity, especially in Vionnaz (Switzerland). A modern large-scale facility for the manufacture of peptides and oligonucleotides (Building «K» – TIDES FABrication Plant) with the potential to double the manufacturing capacity will be built at the Bubendorf site. A new site in Switzerland is planned in Eiken (canton of Aargau) and is intended to further strengthen the production network from the end of the decade onward. Bachem is also investing into capacity expansion across its global manufacturing network at sites in Torrance (USA), Vista (USA) and St. Helens (UK).

We are very pleased about this follow-up order and the renewed confidence in our work. Long-term collaborations are important for us and our partners: they enable us to reliably plan the development and utilization of production capacities. The revenues from this collaboration will help us meet our growth targets and strengthen our market leadership in peptides », says Thomas Meier, CEO of Bachem Group. 


About Bachem

Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.


Source: Press Release